Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144
Summary
Minor revisionpanel verdict · 2026-09-01
Review Summary — Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144
Decision: Minor Revision Target venue: In Silico Review strictness: Balanced (3/5) Reviewer panel: condensed (5 reports)
Reviewer Scores
- data_analysis — score 4.0/5 (confidence 4.0/5)
- ethics — score 4.0/5 (confidence 5.0/5)
- reporting_reproducibility — score 3.0/5 (confidence 4.0/5)
- scientific_validity — score 4.0/5 (confidence 4.0/5)
- contribution_context — score 4.0/5 (confidence 4.0/5)
Panel average: not used; individual scores are advisory
Editorial Audits
- Citation Integrity Auditor — see full Markdown audit
- Methods Completeness & Reagent Traceability Auditor — see full Markdown audit
Estimated cost: $2.0323 Prompt cache: 475,670 tokens read, 194,988 written (51% of 927,072 input tokens served from cache)